We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Global Blood Gas and Electrolyte Analyzers Market to Surpass USD 2 Billion by 2023

By LabMedica International staff writers
Posted on 17 Aug 2021
The global blood gas and electrolyte analyzers market was valued at USD 1.43 billion in 2016 and is projected to register a CAGR of 5.7% from 2017 to 2023 to reach USD 2.1 billion by 2023, driven by an increase in patients suffering from chronic diseases and improvement in healthcare facilities.

These are the latest findings of Allied Market Research (Portland, OR, USA), a market research and advisory company.

Blood gas analyzers are used to measure different parameters, such as pH, blood gas (pCO2 and pO2), electrolytes, and metabolites, from the whole blood samples. More...
An increase in patients being treated in ICUs, NICUs, and emergency departments; rise in patients suffering from chronic diseases; technological advancement in blood gas & electrolyte analyzers, and increase in the number of product approvals are the major factors driving the market growth. However, complexities involved in the interpretation of data are restraining the market growth. Nevertheless, an increase in investment by major medical diagnostics giants and improvement in healthcare facilities in Asia-Pacific is providing growth opportunities for the global blood gas and electrolyte analyzers market.

Based on modality, the portable analyzer segment accounted for the highest share of the global blood gas & electrolyte analyzers market in 2016. On the basis of product/brand, the ABL Flex segment contributed the highest revenue to the global market in 2016. Based on end user, the hospitals segment holds the highest share in the global blood gas and electrolyte analyzers market, owing to the rise in number of patients treated in ICUs, NICUs, and emergency departments, where the utilization of blood gas analyzers is higher to treat patients in a critical condition.

Geographically, North America dominated the global blood gas and electrolyte analyzers market in 2016, and is estimated to maintain its dominance during the forecast period. This can be attributed to the higher adoption of technologically-advanced devices, well-equipped healthcare facilities, and rise in admission of patients in ICUs, NICUs, and emergency departments.

Related Links:
Allied Market Research


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
Manual Pipetting Aid
Pipette Controllers macro
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New findings demonstrate that anti-Müllerian hormone (AMH) may help identify which breast cancer patients are most likely to benefit from chemotherapy plus endocrine therapy (Image Credit: Shutterstock)

AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more

Molecular Diagnostics

view channel
Image Credit: iStock

Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth

Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read more

Microbiology

view channel
Image: The QIAstat-Dx BCID GPF Plus AMR Panel is the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance (Photo courtesy of Qiagen)

FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection

Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.